A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

BACKGROUND: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239318/
https://www.ncbi.nlm.nih.gov/pubmed/22123319
http://dx.doi.org/10.1186/1479-5876-9-204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239318/
https://www.ncbi.nlm.nih.gov/pubmed/22123319
http://dx.doi.org/10.1186/1479-5876-9-204

Ejemplares similares